Benjamin Hohl Sells 1,270 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,270 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $27.51, for a total transaction of $34,937.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $281,097.18.
• On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.27, for a total transaction of $103,147.50.
• On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.33, for a total value of $50,660.00.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.54, for a total value of $95,795.00.
• On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.53, for a total value of $27,282.23.
• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $26.68, for a total transaction of $140,070.00.
• On Friday, July 12th, Benjamin Hohl sold 3,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.07, for a total transaction of $75,210.00.

Enliven Therapeutics Trading Up 2.0 %

NASDAQ:ELVN traded up $0.56 during midday trading on Tuesday, hitting $28.01. 174,035 shares of the company were exchanged, compared to its average volume of 261,678. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $28.51. The company has a market capitalization of $1.32 billion, a PE ratio of -14.51 and a beta of 1.10. The company has a fifty day simple moving average of $23.22 and a 200 day simple moving average of $22.08.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. As a group, equities research analysts expect that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on ELVN shares. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. Robert W. Baird assumed coverage on Enliven Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price target for the company. Finally, Baird R W upgraded Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently modified their holdings of the business. Quest Partners LLC grew its holdings in shares of Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after buying an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Enliven Therapeutics by 67.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after acquiring an additional 3,189 shares during the period. EntryPoint Capital LLC acquired a new stake in Enliven Therapeutics during the 1st quarter worth approximately $167,000. SG Americas Securities LLC purchased a new position in shares of Enliven Therapeutics in the 3rd quarter valued at approximately $256,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Enliven Therapeutics in the second quarter valued at approximately $322,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.